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Introduction
The rising demand for drug testing comes from pressure
from society to stem the spread ofsubstance abuse and to
provide people with greater protection. In response to
this demand, urinalysis testing programmes have been
implemented by a variety of organizations, such as
business and industrial employers, the transportation
industry," police and fire departments, the military, and
sports [1-7]. The drugs most commonly tested for are
marijuana, cocaine, amphetamines and narcotic anal-
gesics. Some programmes also test for benzodiazepines,
barbiturates and phencyclidine.
A common denominator is the widely accepted notion
that drug testing will identify the primary offenders. The
extent to which this objective is achieved is most
appropriately addressed by specialists in behavioural
medicine and sociology. The scientific basis for urinalysis
programmes is in the domain of clinical and analytical
chemistry.
The analysis of body fluids for drugs takes place in two
distinctly different environments: the medical model and
the penalty model. In the former, and in the context of
patient care, the physician requests the test and the
patient is both fully co-operative with the sample
collectors and highly motivated to provide the ideal
sample. In the latter case, the request usually comes from
a non-medical authority and it may not be in the best
interest of the individual to submit a valid sample. In the
medical model the information obtained from the test is
used to assist the physician in the care and management
of the patient. In contrast, in the penalty model the
results are used to impose some penalty to the individual.
This fundamental difference, together with legal impera-
tives, has broad implications for the overall design and
implementation of a drug testing programme.
Although it may seem counter-intuitive, testing in the
penalty model is far more demanding and difficult than
with the medical model. For example, ifa physician sends
a sample from an unconscious patient to the laboratory
for a rapid screen, and, one hour later, the report is
positive for opiates by immunoassay the physician will
use this information to tailor treatment to an opiate
overdose, as opposed to, say, a barbiturate overdose. It is
relatively unimportant to know if the primary drug is
morphine or codeine because the clinical implications are
very similar. In contrast, if the urine came from a pre-
employment screening programme, it would be ofutmost
importance to know if the positive test was due to the
consumption of heroin, a dangerous and illicit drug, or
codeine, a drug which is widely available and commonly
prescribed for pain. In fact, since urinary morphine could
arise from the ingestion of morphine, heroin, or codeine
the complete.analysis of this sample requires a specific
and quatitative analysis for all metabolites of all three
substances. Furthermore, this type of analysis virtually
requires gas chromatography-mass spectrometry (GC-
MS), a technique which is inherently difficult, labour
intensive, and expensive. Thus the complete analysis ofa
complex sample is generally beyond the traditional scope
of hospital- or clinic-based clinical chemistry labora-
tories, and serves to emphasize that the clinical chemist
who wishes to extend his practice to drug testing must be
prepared for a substantial increase in analytical instru-
mentation and technical training. Further amplification
ofthis point appears in numerous recent publications and
reviews [3,4,8].
Additional factors which must be considered in the
testing with penalties model include constant scrutiny by
the legal community, the activity of regulatory agencies,
scrupulous attention to chain of custody both within and
without the laboratory, space allocation to provide for
specialized functions and security, and development of
substantial knowledge regarding the pharmacology,
pharmacokinetics and metabolism of the substances. In
order to accommodate these considerations the trad-
itional laboratory must reorganize administrative pro-
cedures, job descriptions, security, laboratory protocols
and space allocation.
Urine testing of sportpersons (doping control) differs
from that ofemployees in that the main reason to test is to
maintain fair play by prohibiting the use ofperformance-
enhancing drugs, as opposed to protecting safety or
productivity on the job by prohibiting street drugs. In
marked contrast to testing for the so-called ’drugs of
abuse’, the menu ofdrugs tested for by sport authorities is
both comprehensive and includes several classes of
substances [1,9]. Some banned substances are also
produced endogenously (for example testosterone), and
in the case of several substances the ban is based on
quantification. Detection of the administration of exo-
genous testosterone requires special testing techniques
[8,10,11].
The current list of substances banned by the Inter-
national Olympic Committee consists of six groups [8],
i.e. the stimulants where several classes are found such as
the psychomotor stimulants (for example amphetamine),
the sympathomimetics (for example ephedrine), and the
analeptics (for example strychnine, caffeine). The other
groups are narcotics, anabolic steroids, beta-blockers,
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diuretics, and certain peptide hormones. This classifica-
tion is based on the expected effect of the drugs on the
athlete, as opposed to their chemical structure and
properties.
directly observed by a drug testing team member of the
same gender [15]. Some organizations go to further
extremes and require removal of all clothing. Others do
not directly observe urination, but use temperature-
sensitive containers [5].
Regulatory considerations
Legal review can be expected 12], so laboratory directors
should be familiar with the relevant local, national and
international laws. In general, such reviews are designed
to find fault with any aspect of the system, and, in
particular, the authority to test, provisions for individual
consent to undergo testing, collection procedures, chain
of custody, sample chemistry, instrument maintenance,
tuning, and calibration records, quality control, the
analytical data consisting ofchromatograms and spectra,
sample storage, qualification of laboratory personnel,
confidentiality, and appeal process. Laboratories are
advised to review carefully the documents which describe
the authority to test and the details of the client’s
protocol. The best defence for an unfavourable legal
decision is excellence in analytical chemistry, together
with a complete set of written procedures covering all
aspects of the testing programme, and documentation
showing that all procedures were followed.
Various countries and scientific organizations either have
produced or are in the process of preparing guidelines to
regulate drug testing laboratories [2,4-6]. These are
designed to protect the person tested (’testee’) by
improving the quality ofthe work product by emphasis on
quality assurance, quality control, proficiency testing,
and documentation. In some countries the guidelines are
incorporated into accreditation or certification pro-
grammes [5]. Consumers of laboratory services are
encouraged to use only those that are certified or
accredited.
Sample collection procedures
Prior to urine collection the testee is offered the oppor-
tunity to declare all medications and related substances
taken recently. This information becomes part of the
documentation, and, in the event of a positive test and
legal action, it is used by the certifying scientist to
evaluate the possibility of analytical interferences or
inadvertent use of a banned substance.
It is essential to ensure that the urine tested is authentic
urine from the designated individual. Experience has
shown that some individuals will attempt to evade
submitting authentic urine by techniques such as con-
cealing bladders and tubing under their clothing and
even introducing ’clean’ urine into their bladder just
before the test 13]. To help exclude these measures, and
other forms of substitution, the testee should remain
under the constant supervision of at least one member of
the drug testing team from the time of notification to the
time of urination. Next the drug testing official must
verify the identity of the testee by requesting a passport,
driver’s licence, or otherwise accepted document with
photograph. Finally, the actual urination should be
To ensure sample integrity, the urine collection con-
tainers should be individually sealed. The testee is given
the opportunity to select any container which is used to
collect or ship the specimen. No one but the testee should
handle the urine in the container and/or the bottles until
they are sealed. The testee and officials all sign a
declaration that protocol was followed to their satisfac-
tion. The laboratory should not know the identity of the
testee, therefore urine samples are forwarded to the
laboratory identified only by a number. The organization
retains the confidential master code which links each
number to an individual’s name. To exclude all varieties
of sabotage, the collection area should be secure with
restricted access.
Because there are manipulations which affect renal
excretion and the urinary concentrations of the forbidden
drugs, some drug testing programmes require that the pH
and specific gravity be within a specified range and may
require holding the testee to provide additional urine that
fulfills the criteria. For example the extretion of many
nitrogen-containing drugs depends on urine pH. If the
urine is alkaline, certain stimulants are excreted less,
therefore a testing program may not accept a sample ifthe
pH is 7.5 or greater. Another example is that of dilution
by diuretics or excessive liquid intake, such that 1.005
may be the lowest acceptable specific gravity. These
parameters may be measured with a dipstick on the urine
remaining in the container after all bottles have been
sealed, thus excluding the possibility ofcontamination by
the dipstick. In some drug testing programmes the
specific gravity is not measured at the collection site.
Some laboratories measure specific gravity and/or creati-
nine before proceeding with the analysis, and, they may
use this data to determine if the sample is valid. The
laboratory must receive a sufficient volume to complete
all tests. Most protocols define a minimum acceptable
volume.
For the additional protection of the testee, many organi-
zations require the division of the urine sample into two
parts, A and B, to be sealed individually. The laboratory
ordinarily receives both, saves the B intact, analyses the
A, and reports the results to the organization.
Chain of custody
To ensure that the urine tested suffered no contamina-
tion, tampering, or mislabelling, the chain of custody
begins at the collection site and ends with the final report.
The sample is handled at first only by the testee until
sealed, then by collection site officials, transportation
personnel, and laboratory technicians. The control
system must guarantee integrity of the specimens from
the moment of submission of the urine until the
conclusion of the analysis. Each transfer must be
documented, including within-laboratory transfers.
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Experienced couriers are recommended for the trans-
portation ofsamples to the laboratory. A chain ofcustody
form and manifest are initiated at the collection site. The
laboratory checks the custody form, examines the pack-
age for evidence of tampering, and then accepts custody
ofthe package. After opening the package the samples are
inspected individually and checked against the manifest.
At this juncture the laboratory initiates its internal chain
of custody. Once the chain is initiated, only qualified
laboratory personnel may work with the sample and no
unauthorized visitors are allowed in the work area. The
laboratory must be able to give exact documentation on
such details as where a certain sample was located at a
given time and the identity of the person handling the
sample at the time in question. The samples should be
stored at a maximum of 4C in a locked area.
Analytical approach
Urinalysis for banned drugs must be done using methods
that give firm evidence because of the consequences to
lives, careers, and reputations which follow reports of
positive analytical findings. A screening test divides the
samples into two categories: a large group of analytically
negative samples, and a smaller group that requires
further analysis (confirmation test). In the latter case, the
screening data indicate that a banned substance or its
metabolites may be present and provide tentative identi-
fication. The principles ofdecision theory have been used
to calculate the predictive value of screening and
confirmation tests [14]. Confirmatory tests are time-
consuming, complex, and have one main goal: they
provide data for the final, unequivocal identification of
the banned substance or metabolites. In addition,
confirmatory tests are used to confirm the identity of the
biological sample (for example that the urine used for the
second analysis is the same as the one used for the first
analysis), to exclude clerical errors, and to confirm that
the analysis is reproducible.
Sample preparation
Glassware must be scrupulously clean. False positive
results have been traced to soap residues [4]. To avoid
contamination with phthalates nothing but glass or
Teflon should come into contact with the sample. The
purity of the solvents and reagents should be appropriate
to the analysis. Sample preparation is specifically
designed in an attempt to optimize the detection of each
chemical class of substance. If the drugs and metabolites
are excreted as conjugates (sulfates or glucuronides), a
hydrolysis step is necessary prior to extraction. Com-
pared to acid hydrolysis, enzymatic hydrolysis is usually
less destructive to deconjugated products. Polar com-
pounds containing hydroxyl, keto, acid, or amine func-
tions are usually converted to less polar and more volatile
derivatives. The most common derivatizations are
trimethylsilylation, trifluoroacylation, and methylation.
Many unconjugated nitrogen-containing compounds
may be extracted with diethyl ether at pH greater than
12, separated by GC, and detected with a nitrogen
phosphorus selective detector (NPD). Acidic compounds,
for example barbiturates and benzodiazepines, require
extraction at appropriate acidic pH. Amphoteric com-
pounds, such as morphine, are extracted most efficiently
at their isoelectric point with polar solvents such as ether
and propan-2-ol. Conjugated nitrogen compounds (beta-
blockers, opiates, hydroxylated phenylalkylamines) may
be extracted after hydrolysis with diethyl ether, deriva-
tized by trimethylsilylation and/or trifluoroacylation,
separated by GC, and detected by NPD. Many diuretics
are acidic compounds and are extracted at a pH lower
than 2. Because of their low volatility and thermolability
they are not amenable to GC analysis without deriva-
tization. Diuretics may be screened for by HPLC with
UV detection or by GC and/or by GC-MS.
Screening tests
Most of current screening tests are based on immuno-
assay or chromatographic techniques.
Immonoassay (IA): This is the most commonly employed
screening test [3]. A variety of IA-based methods have
been developed and automated. One common feature of
IA is the utilization of antibodies with specificity for the
drug and/or metabolite and closely related substances.
Since the antibodies cross-react with substances which
are similar in structure to the target substance, the
analytical results are neither unambiguous nor strictly
quantitative and must be confirmed. A variety of
interferences have been described (e.g. [15]).
Chromatography: The different kinds of chromatography
(for example TLC, GC, LC) are basically separation
techniques used to resolve complex biological mixtures.
With appropriate physico-chemical detection and with
strict standardization of experimental parameters identi-
fication and quantitation can be achieved.
(1) Thin layer chromatography (TLC) is a common
screening test for drugs ofabuse. After an extraction at
controlled pH, a tentative identification ofdrugs can be
made based on physico-chemical characteristics (Rf
values) and colour reactions.
(2) High performance liquid chromatography (HPLC)
is ideally suited for thermolabile and polar substances.
It is most commonly used in a modification known as
reverse phase chromatography. The conditions may be
adjusted to solve a wide range of analytical separation
problems. The available choice of detection UV/
visible, fluorescence, electro-chemical, chemical detec-
tion, and MS--will allow sensitive group or even
substance detection.
(3) Gas chromatography (GC) will separate thermo-
stable drugs that are sufficiently volatile to be eluted
from the analytical column. Fused silica capillary
columns provide the necessary high resolution to
separate extremely complex mixtures or biological
matrices. Polar substances need derivatization prior to
GC. With element-specific detectors (for example
NPD) or in combination with a MS, selective and
sensitive detection ofa wide variety ofdrugs is possible.
Confirmation tests
In confirmation tests the unknown and the standard
undergo simultaneous sample preparation from extrac-
tion to derivatization followed by analysis. Evidence of
87D. Catlin et al. IFCC--Testing urine for drugs
the presence of a compound includes multiple measures
of similarity, such as instrumental analysis data and
relative amounts (or concentrations) of multiple urinary
metabolites.
Although several approaches may be used to confirm the
presence of substances in urine, gas chromatography-
mass spectrometry (GC’MS) is currently the method of
choice for unambiguous identification. It is the combi-
nation of two techniques, where the MS is used as a
detector for the GC. GC separates the components of a
mixture and introduces them one by one into the mass
spectrometer, which records a mass spectrum or ’finger-
print’ of each isolated component. Properly performed
GC-MS analysis unequivocally identifies the compound,
not just the drug class or chemical family. For the
confirmatory analysis an extract from a new aliquot of
urine is prepared using the same protocol as for the
screening procedure, or using an appropriate alternative.
GC provides two elements of identification: RT and
RRT. The GC retention time (RT) of a compound is the
time elapsed between injection ofthe extract into the inlet
and appearance of the compound at the outlet. It is
reproducible under equal operating conditions. If an
unknown has the same RT as the standard it may be the
same substance or it may be a different one. Ifan internal
standard is present in both the unknown extract and the
standard extract, one can calculate the relative retention
time (RRT) as: RT (compound)/RT (internal standard).
The RRT is more reproducible than the RT. If an
unknown has a RRT different from the RRT of the
standard it is a different substance. The main determi-
nant ofRT and RRT is column polarity. Another means
of characterizing a substance is retention index as
originally described by Kovats [6] and later modified and
improved by various authors [17]. This is useful because
it allows comparison with the scientific literature.
Mass spectrometry is a very powerful technique, but
many of its capabilities cannot be realistically applied on
a large scale for routine work. The two most frequently
employed ionization techniques are electron impact and
chemical ionization. The electron impact mode is com-
monly used to obtain a full scan. Chemical ionization is
particularly useful to confirm the molecular weight of a
substance.
Most mass spectrometers can give an interpretable full
scan spectrum with less than one nanogram of material.
However even greater sensitivity can be achieved by
monitoring only a few characteristic ions of the suspected
compounds in the selective ion monitoring (SIM) mode.
Data collected in the SIM mode may not be considered as
sufficient proofof positive results by the most demanding
chemists, nevertheless SIM data are commonly presented
to document a positive finding and this is acceptable to
many regulatory bodies and scientists. If the analysis is
based on SIM data, the certainty is greatly enhanced if
more than one characteristic substance is found in the
sample, for example the parent drug and a metabolite. In
addition if SIM data are used it is important to
demonstrate equivalence between ion ratios for the
sample and a standard. Furthermore one should demon-
strate that the ion of interest dominates its region by
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monitoring the ions immediately preceding and following
it. This shows that the pertinent ion is not derived from
the preceding ion, and that the following ion is present in
the proper ratio to the pertinent ion.
Unambiguous identification is accomplished by match-
ing the RRT and spectra ofthe identified substances with
those of authentic reference standards concurrently
extracted from spiked urines (positive quality control) or
certified positive cases. The reference spectra are con-
tained in a mass spectral library. Such a library should be
developed in each laboratory by analyzing derivatized
compounds or their metabolites under comparable oper-
ating conditions. Ifreference standards ofmetabolites are
not available, clinical studies may be performed by
administration of the parent drug to man followed by
timed urine collections, and the resulting urines used as
positive quality control samples.
Quality assurance
Quality assurance is ’planned and systematic actions
necessary to provide adequate confidence that a product
or service will satisfy given requirements for quality’
18,19]. Quality assurance encompasses quality control
(QC) and quality assessment. The overall aim is to
ensure that the analytical results are ofsufficient accuracy
for their intended application. The goal of quality
assurance in drug testing is to minimize and document
the probability of false positive and false negative results,
as well as to document compliance with good laboratory
practices (GLP) and the requirements of regulatory
agencies. Quality is a team work ethic which materializes
in various forms in all aspects of the work. Quality
assurance may be implemented by a designated senior
scientist and manager. Some laboratories refer to such
individuals as QA officers.
In the context of large drug testing programmes, for
example those operated by governments, sport authori-
ties, and military establishments, quality is monitored by
accreditation and proficiency testing programmes that
establish requirements of competence and equivalency
for the protection of the organization conducting the
testing and of the individuals tested. Usually the
requirements cover personnel needs and qualification
and material resources (for example instruments) and
analytical capabilities specific to a finite list ofsubstances
at specific concentrations. Compliance is documented by
on-site inspection and written reports. Failure to comply
results in immediate restriction of the work. The profi-
ciency testing aspect of the programme utilizes biological
samples prepared to contain known amounts of specific
banned substances. The samples are sent to the labora-
tory in the blind (unknown to the laboratory) or open
(known to the laboratory) mode. Proficiency testing
programmes document the strengths and deficiencies of
the participating laboratories, and provide objective data
for between laboratory comparisons [20,21].
Critical review ofQC data and optimization ofQC design
should be a constant and integral part of the work of a
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written Standard Operating Procedures (SOP) which
describe each protocol in unique, detailed, and manda-
tory terms. Technicians are expected to adhere to the
SOP. Laboratories should utilize internal QC biological
samples either blind (to those doing the analyses) or
open. Good quality control procedures monitor all
possible sources oferror and provide for rapid isolation of
the problem. At least 10% of the samples in a batch are
related to QC. Such procedures assess: clerical accuracy,
sample preparation recovery, chromatographic perfor-
mance, mass spectral sensitivity, overall assay detection
threshold, and precision in quantitation. Examples of
independent cross-checks are overlapping successive
batches of QC samples or requiring verification by two
persons. Record-keeping should include QC data and the
description ofmeasures taken to correct actual problems.
Interpretation of test results
Pharmacok netics
In theory, complete knowledge of the pharmacokinetics
ofa drug enables a precise prediction ofthe concentration
of drug in urine at various times after drug admini-
stration. In practice, however, many relevant variables
cannot be known and the predictions become relatively
gross estimates. Nevertheless, knowledge ofthe principles
of pharmacokinetics enables the person responsible for
interpreting the results of a drug test (the interpreter) to
provide the most complete and accurate report and
assessment.
The concentration of drug in plasma at various times
after intravenous drug administration is determined by
the dose and clearance (a pharmacokinetic variable that
encompasses half-life and volume of distribution) [22].
The concentration in urine may also be estimated if
clearance of drug and water are known. If the drug is
orally administered the model must include bioavail-
ability and the rate of absorption. Sophisticated pharma-
cokinetic models can also account for multiple and
variable doses and dosage intervals [22,23]. Drugs with
long half-lives and/or large volumes of distribution may
be detectable in small amounts in urine for months.
Examples of studies which provide useful pharmaco-
kinetic data are: marijuana [24-26], cocaine [23,27],
amphetamine [28]. Reviews [3,6,8] provide additional
references.
Many of the relevant variables are rarely known,
therefore the interpreter evaluates the pattern of excre-
tion of drug and metabolites as determined by clinical
studies. One must consider the sensitivity of the assays
since it is a major determinant ofdetection times. Clearly
a large dose will result in a positive test for a longer time
than a small dose. Multiple closely spaced doses will
result in drug accumulation, an increase in total body
burden, and longer detection times. For example urine
collected within the first few hours after cocaine administ-
ration contains both cocaine and benzoylecgonine, while
urine collected a several hours later will not contain
detectable amounts of cocaine [27]. The principal
metabolite of tetrahydrocannabinol (ll-nor-delta-9-
tetrahydrocannabinol-9-carboxylic acid) is usually detec-
table for one or two days after single exposure, however
multiple exposures may lead to a positive test for two or
more weeks after cessation [25]. In addition passive
exposure to marijuana smoke may result in sufficient
absorption to result in detectable amounts of marijuana
metabolites in urine [29].
Single doses ofmany anabolic steroids result in a positive
test for between one and three days, while multiple doses
result in positive tests for many days or weeks. Steroids
that are formulated in oil and administered by injection
may be detectable for several months.
Drug metabolism
The majority of drugs are lipophilic and undergo
oxidative metabolism resulting in more polar, ionizable
metabolites which are either eliminated as such or after
conjugation. Alterations in the rate and extent of drug
metabolism influences the elimination half-life and clear-
ance ofdrugs, and as a consequence, the concentrations of
parent drug and of metabolites in blood and in urine.
About 90% of all oxidative metabolic reactions are
catalysed by the cytochrome P450 enzyme system present
in endoplasmic reticulum of liver cells, therefore this
enzyme system plays a central role in the metabolism of
lipophilic drugs such as stimulants, beta-blockers, ster-
oids, opioids and other drugs.
Comprehensive knowledge of the metabolism of each
banned substance is essential to the interpretation ofdrug
testing results. For example the ingestion ofsome types of
poppy seeds results in morphine in the urine [30]. Since
morphine is a major metabolite ofheroin, the detection of
morphine is compatible with administration of heroin or
the ingestion of poppy-seed products. One way to clarify
this situation is to analyse the urine for 6-monoacetylmor-
phine, which is a metabolite of heroin and not a
metabolite of morphine, and not found in poppy seeds
[31].
Drug interactions
The best studied drug interactions known to markedly
influence drug or metabolite concentrations in body
fluids are inductions and inhibitions of enzymatic reac-
tions catalysed by cytochrome P450. Induction results in
a decrease in half-life (increase in clearance) and more
rapid elimination from the body. Furthermore induction
often changes the pattern of metabolite elimination.
Substances well known to induce the P450 system include
drugs such as barbiturates, glutethimide, carbam-
azepine, ethanol and phenytoin (hydantoins) and envir-
onmental chemicals, such as polycyclic aromatic hydro-
carbons (3-methylcholanthrene, benzo(a)pyrene) and
polychlorinated aromatic hydrocarbons (polychlorinated
biphenyls).
The inhibition of oxidative drug metabolic reactions by
relatively unspecific inhibitors like cimetidine, chloram-
phenicol or sulfonamides will increase drug half-life and
increase blood levels ofthe inhibited drug. This results in
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a decrease in the concentration of both parent drug and
metabolites in urine, and therefore the ability to detect
drug use. Furthermore the individual may experience
enhanced drug effects and/or toxicity.
A number of clinically significant drug interactions
resulting from concomitant administration of cimetidine
with drugs such as caffeine, beta-blockers, barbiturates,
morphine, and ethanol have been described [32]. The
mechanism of inhibition is an interaction of cimetidine
with the heme iron in cytochrome P450 [33]. Like
cimetidine, the anabolic steroid stanozolol interacts with
cytochrome P450 and is a potent inhibitor ofcytochrome
P450-catalysed reactions [34]. Depending of the particu-
lar isoenzymes of that are inhibited stanozolol could alter
the elimination of other anabolic steroids.
Interactions involving drugs that influence the pH and
water metabolism of the body alter the excretion rates of
many banned drugs. The urinary excretion of many
drugs is markedly influenced by urine pH [22,28,35,36].
The excretion of basic drugs (for example amphetamine)
decreases as the pH of urine increases. Bicarbonate has
been used to rapidly change the excretion rate of basic
drugs and thereby reduce the likelihood ofa positive test.
Similarly the excretion of acidic drugs (for instance some
diuretics) is retarded by low urinary pH. Other drugs
influence the excretion of anionic substances. For
example probenecid and related substances temporarily
decreases the tubular excretion of anabolic steroids,
penicillins, indomethacin and others. Some drug users
attempt to avoid detections by adding adulterants
directly to urine [15].
The state ofhydration ofan individual, by its effect on the
water content of urine, markedly influences the concen-
tration of drugs. Indeed, excessive intake of fluids is
commonly used to dilute the urine and lower the
concentration of drugs. Similarly diuretics have been
used to rapidly dilute the urine. Some .testing
programmes routinely measure the specific gravity of
urine to provide some insight into this problem. Measur-
ing the urinary creatinine and reporting the concent-
ration ofdrug per mg ofcreatinine is another technique of
factoring for the effect of dilution.
Consideration of the pharmacokinetics, pharmacodyna-
mics, metabolism, and drug interactions leads to the
conclusion that it is very difficult to answer the question
ofwhether or not an individual was under the influence of
the drug at the time the sample was taken. Given
sufficient analytical data and using tenable assumptions,
the interpreter may be able to offer a reasonable opinion
on this question.
Documentation of results
The analytical report should be limited to statements of
fact so as not to be confused with opinion. Therefore,
where necessary, two distinct documents should be
provided. The analytical results and other observations
are normally documented in the analytical report,
whereas matters of opinion should appear in a letter
which accompanies that report.
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Content of the analytical report
The analytical report must provide sufficient information
to enable the recipient to identify the individual(s) from
whom the sample(s) described in the report originated.
To avoid transcription errors all code numbers should be
checked and double-checked by two persons. A complete
description of the testing occasion is the best way to
prevent such errors.
The report will contain chain-of-custody information
including the date and time ofarrival ofthe samples in the
laboratory so that the analytical report may be linked to
other chain-of-custody documentation. The integrity of
the samples will be documented by including statements
that the samples were sealed and, where appropriate,
recording the seal numbers or other identifying features.
The type(s) of assay performed must be stated either
explicitly or, where an accepted protocol has been
established, implicitly.
Qualitative results
Either the absence ofthe substances or the presence ofthe
chemical entities identified in the individual samples
must be clearly stated. Examples of appropriate state-
ments might be:
’No substance banned by the (insert name oforganiza-
tion] was found in any of the samples.’
’The sample coded 2345A was found to contain [insert
proper name] as described in the details attached. No
substance banned by the [insert name oforganization]
was found in any of the other samples.’
The proper name should be the IUPAC name of the
chemical entity identified or ifthe identified substance is a
parent drug (as distinct from a metabolite of that drug)
then the International Non-Proprietary Name (INN)
might be used instead. Under some circumstances the use
of the IUPAC name is cumbersome. In these cases, it
may be convenient to use the INN.
It is customary for supporting data tobe included, such
as chromatographic data and GC-MS data obtained from
the sample specified, and, in addition, data on corres-
ponding reference standards (or reference urines
obtained from suitable excretion studies). The reference
data would normally be obtained after the specified
sample has been analysed with suitable precautions to
exclude the possibility of contamination. A sufficient
description of the analytical methods used should be
presented to enable the chromatographic and mass
spectral data to be interpretable.
Quantitative results
Many drug testing programmes define a particular
concentration ofdrug or metabolite as the dividing value
for reporting a urine result positive or negative. This
value, which is often referred to as the cut-off, represents
an administrative decision on the part ofthe programme.
The cut-off may be considerably greater than the
detection limit (lowest concentration that can reliably be
detected) of the assay. Cut-off concentrations may applyD. Catlin et al. IFCC--Testing urine for drugs
to the screening test and the confirmation test. For
example the IA cut-off for cocaine in the US department
of Defense program is 300 ng/ml and the corresponding
cut-off for benzoylecgonine by GC/MS is 150 ng/ml [4].
This leads to the terminology ’analytical positive’, which
refers to a sample containing detectable amounts ofdrug,
but which is reported or considered negative by the
programme.
Ifthe quantitative results are greater than the cut-off, at a
minimum the sample is reported positive, or more
informatively--substance detected. It is more informa-
tive to report that the substance was detected at a
concentration greater than the cut-off. Clearly, the
concentration must exceed the cut-off by more than the
experimental variation. In all other cases, the mean ofthe
measured values should be stated together with an
estimate of the precision, for example relative standard
deviation (coefficient of variation) or confidence interval
for the measurements.
If quantitative results are being reported and the
substances under investigation are present in concen-
tration which are less than the cut-off value but greater
than the detection limit, then the results should indicate
that fact in the format of--substance detected, not greater
than X (where X is the cut-off defined by the pro-
gramme). In this case the sample is positive by analytical
criteria, but negative by administrative criteria. It is
informative to report the detection limit of the laboratory
for that specific substance at that time. The substance
should not be reported as being not present or even not
detected.
Supplemental information and opinion
Avoid including in the analytical report irrelevant
findings since they might be misinterpreted or confusing.
Similarly, do not include in the analytical report the
finding of endogenous or even ubiquitous substances
except and unless the analytical protocol so demands, for
example where concentration limits are imposed and/or
where administration of a substance which is indis-
tinguishable chemically from an endogenous substance is
suspected (testosterone for instance).
Any additional information or statements ofopinion may
be expressed in a separate document, for example a
covering letter. Examples of information which might be
relevant include:
(1) Highlighting a declaration which has accompanied
the samples such as a medical certificate, or drug
declaration by the individual who has provided the
sample where this is relevant and the laboratory data
supports that statement.
(2) Where a chemical entity has been found and
detailed in the analytical report, and the presence of
this substance is considered to be a characteristic
metabolite ofa present drug subject to control, then an
appropriate statement should be given with supporting
literature references, for example ’11-nor-delta-9-tetra-
hydrocannabinol-9-carboxylic acid is a metabolite of
THC’, or, ’the presence of 19-norandrosterone (3-
alpha-hydroxy-5-alpha-estran-17-one) is considered to
be evidence of the administration of the anabolic
steroid nandrolone’.
No statement about the intent ofthe individual providing
the sample should be made. The laboratory should
restrict its report to the sample provided (other than as
described above). It is generally unwise to make any
unsolicited comments about the time when the last
administrations might have occurred since there is
unlikely to be any supporting information, for example
dose taken, size ofindividual, metabolic characteristics of
individual available to the laboratory at that time.
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